Drug Profile
Research programme: protein therapies - CureVac
Alternative Names: Protein replacement therapy - CureVac; RNAntibody®; RNArt®protein therapy; Sequence engineered mRNA - CureVacLatest Information Update: 28 Dec 2020
Price :
$50
*
At a glance
- Originator CureVac
- Developer Acuitas Therapeutics; CureVac
- Class Proteins
- Mechanism of Action Protein replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer; Rabies; Unspecified
Most Recent Events
- 28 Dec 2020 No recent reports of development identified for preclinical development in Cancer in Germany (Parenteral)
- 28 Dec 2020 No recent reports of development identified for preclinical development in Rabies(Prevention) in Germany (Parenteral)
- 28 Jul 2019 No recent reports of development identified for preclinical development in Unspecified in Germany (Parenteral)